Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Carolien Beukhof,Robin Peeters,Kemenade Folkert Van,Tessa Brabander,Nederveen Francien Van,Rijke Yolanda De,Lideke Froberg,Velthuysen Loes Van,Boen Kam,Herder Wouter De

doi:10.1530/endoabs.56.gp230

Abstract

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Highlights

For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients
111In-DTPA-octreotide scans We retrospectively reviewed 111In-DTPA-octreotide scans between 1999 and 2011 of non-treated MTC patients that were performed in metastatic MTC
This study reports the results of 10 patients with metastasized MTC that were treated with Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-octreotate

Summary

Introduction

For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has been suggested to be a useful treatment for MTC, is usually well tolerated, but evidence on its effectivity is very limited. In a second trial treating 7 MTC patients with 177Lu-octreotate, 3 patients had PR, 3 patients had stable disease (SD) and 1 patient progressive disease (PD) [14] These results suggest that PRRT might be a useful treatment in patients with MTC, the total number of treated patients is very limited so far. We performed a retrospective evaluation of treatment with 177Lu-octreotate in our center, where it was used in a highly selected group of 10 MTC patients with progressive disease or high risk tumor localization. We evaluated possible predictors and pitfalls of 177Lu-octreotate treatment in MTC

Methods

Results

Discussion

Conclusion